Figure 1From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers SDS-PAGE analysis of peptic digest of panitumumab IgG. Panitumumab was subjected to digestion with 2% pepsin at 37°C. At the specified time points, samples were neutralized and stored at 4°C until analyzed. The peptic digests were analyzed under non-reducing (a) and reducing (b) conditions.Back to article page